The largest database of trusted experimental protocols

25 protocols using bq788

1

BQ123 and BQ788 in Spinal Cord Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols
BQ123 and/or BQ788 (both from Sigma, St. Louis, MO, USA) dissolved in sterile phosphate-buffered saline (PBS) were administered to corresponding SHAM and SCI mice (SHAM + BQ123, SHAM + BQ788, SHAM + BQ123 + BQ788, SCI + BQ123, SCI + BQ788 and SCI + BQ123 + BQ788) via intraperitoneal injection (10 mg/kg, respectively) (27 (link)–29 (link)) at 1 day before SCI and then further treated once a day for 6 weeks for behavioral testing or for the indicated time-points (2, 4, 6 and 24 h and 4 days) for other experiments post-injury. PBS for vehicle control (VEH) was administered in corresponding SHAM and SCI mice (SHAM + VEH and SCI + VEH). Significant side effects resulting from BQ123 and/or BQ788 treatment, such as changes in body weight or an increase in mortality, were not observed during our experiments.
+ Open protocol
+ Expand
2

Human Cardiac Myocyte Experiments

Check if the same lab product or an alternative is used in the 5 most similar protocols
HCMs were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA) and grown in cardiac myocyte medium supplemented with 5% fetal bovine serum (FBS), 1% cardiac myocyte growth supplement, and 1% penicillin/streptomycin solution. Cells were cultured on a poly-L-lysine-coated dish in a humidified incubator with 5% CO2 at 37°C. Cells between passages 3–5 were used in all experiments. The Safety Committee of Biological Experiments at Kaohsiung Medical University approved the use of HCMs for in vitro experimental use. The following drugs were used: fenofibrate (a PPARα agonist, Sigma), GW6471 (GW, PPARα antagonist, Santa Cruz), BQ-123 [BQ123, endothelin A receptor (ETA) antagonist, Sigma], BQ788 [BQ788, endothelin B receptor (ETB) antagonist, Sigma], PD98059 (ERK inhibitor, Cell Signaling), and SB203580 (p38 inhibitor, Cell Signaling). None of these drugs significantly influence cell viability (>90%).
+ Open protocol
+ Expand
3

Endothelin Receptor Antagonists in GDM

Check if the same lab product or an alternative is used in the 5 most similar protocols
The effects of ETA receptor antagonist BQ123 and ETB receptor antagonist BQ788 were assessed on omental arteries collected from pregnancies complicated by GDM (treated with insulin, n = 5) and healthy gestation-matched controls (n = 3–8). To investigate differences in the function of ETA and ETB receptors in GDM, following confirmation of artery integrity [20 (link),21 (link)], arteries were incubated in BQ123 (1 µM; Sigma-Aldrich, St Louis, MO, USA), BQ788 (5 µM; Sigma-Aldrich, St Louis, MO, USA), a combination of BQ123 (1 µM) and BQ788 (5 µM), or vehicle control (ethanol) prior to constriction with recombinant ET-1 (10−11 M to 10−7 M). Following treatment, the antagonist or vehicle control treatment remained in the bath with ET-1 (concentrations as detailed above). Changes in measured constriction were normalized to the pre-determined maximum constriction induced by KPSS.
+ Open protocol
+ Expand
4

Cytokine Inhibition in Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-IL-1β, anti-IL-6, anti-TNFα and anti-CINC-1 antibodies were supplied by R&D Systems Inc. (USA). Indomethacin, AACOCF3 and PACOCF3 were purchased from Biomol Research Laboratories (USA). GM6001 was supplied by USBiological (USA); whereas L-NMMA, HOE 140, Lys-(Des-Arg9,Leu8)-bradykinin, promethazine, methysergide, BQ-123, BQ-788 and fucoidan were purchased from Sigma-Aldrich Co. (USA). Celecoxib was supplied by Searle and Co (Puerto Rico). Zileuton was purchased from Abbott Laboratories (Zyflo®, USA). Carrageenin was purchased from Marine Colloids.
+ Open protocol
+ Expand
5

Circadian Regulation of Metabolic Processes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Male WT and global PER1 KO mice were acclimated to metabolic cages and to receiving I.P. injections. Male mice were given the same HS/DOCP regime as described above. On the 4th day of the HS/DOCP treatment, BQ788 (Sigma) was administered through an I.P. injection at 1.5mg/kg BW dosage at 6pm, the time of lights off and the beginning of the mouse active period. Urine was collected 3hrs later at 9pm. additionally, urine from 6pm-6pm the following day (24hrs post injection) was collected. The dosage of 1.5mg/kg was selected based on previous studies demonstrating 1mg/kg is the minimal effective dose (Vercauteren et al., 2017 (link)). Additionally, higher doses at 3mg/kg led to changes in blood pressure (Okada & Nishikibe, 2002 (link)), and to reduce this effect we lowered the dosage.
+ Open protocol
+ Expand
6

Immunofluorescence Staining of Pluripotency and Cardiac Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunofluorescence staining for pluripotency of iPSCs was performed by using the following primary antibodies: anti‐NANOG (Abcam), anti‐OCT3/4 (Santa Cruz), anti–SSEA 3 (Millipore), anti–SSEA 4 (Millipore), anti–Tra‐1‐60 (Millipore), and anti–Tra‐1‐81 (Millipore). In immunofluorescence staining for cardiac markers, monoclonal anti–α‐actinin (Sigma), monoclonal anti‐cTnT (Thermo Scientific), polyclonal anti‐cTnT (Santa Cruz), monoclonal anti–myosin light chain (MLC)2a (Synaptic Systems), polyclonal anti‐MLC2v (ProteinTech Group), anti‐ANP (Santa Cruz), anti–cMyBP‐C (Santa Cruz), polyclonal anti–cMyBP‐C motif (supplied by C. Witt University of Heidelberg, Heidelberg, Germany), and anti–nuclear factor of activated T cells (NFAT)c4 (Santa Cruz) were used. The isotype‐specific secondary antibodies, Alexa Fluor 488 chicken anti‐rabbit IgG, Alexa Fluor 594 goat anti‐mouse IgG1, Alexa Fluor 488 goat anti‐rat IgM, Alexa Fluor 594 goat anti‐mouse IgM, Alexa Fluor 488 goat anti‐mouse IgG, Alexa Fluor 594 goat anti‐mouse IgG2b, Alexa Fluor 594 chicken anti‐goat IgG, and Alexa Fluor 555 goat anti‐rabbit IgG, were all obtained from Invitrogen. The tested drugs included endothelin‐1 (1.0, 10, 100, or 1000 nmol/L), angiotensin II (100 nmol/L), insulin‐like growth factor 1 (100 nmol/L), phenylephrine (0.05 mmol/L), BQ‐123 (250 nmol/L), and BQ‐788 (100 nmol/L) (all from Sigma).
+ Open protocol
+ Expand
7

Endothelin-1 Regulation in HTR8/SVneo Trophoblasts

Check if the same lab product or an alternative is used in the 5 most similar protocols
The HTR8/SVneo trophoblast cell line was kindly provided by Dr. C.H. Graham, Queen’s University, Kingston, Ontario, Canada26 (link), and maintained in RPMI-1640 medium supplemented with 5% FBS. Cells were starved for 24 hr with 0.5% FBS, then treated with ET-1 at doses of 0.02, 0.1 or 0.5 μM for 18 hr27 (link). Different batches of cells were treated with ET-1 (0.5μM), ET-1 (0.5μM)+BQ123 (a selective EDNRA antagonist, 1μM), ET-1 (0.5μM)+BQ788 (a selective EDNRB antagonist,1μM) 28 (link), 29 (link), and ET-1 (0.5μM)+Bosentan (a non-selective EDNR antagonist, 1μM) 30 (link). Another batch of cells was treated with ET-1 (0.5μM) or vehicle as control. After incubation, medium and cells were collected at 4, 8, 12 and 18 hr for analysis. ET-1, BQ123, BQ788 were purchased from Sigma-Aldrich (St.Louis, MO). Bosentan was purchased from Cayman (Ann Arbor, MI).
+ Open protocol
+ Expand
8

Endothelin Receptor Antagonists in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Adult male C57BL6/J mice (Jackson Labs, age 6–8 weeks) were used for this study. All drugs and vehicles were administered via osmotic minipumps (Model 1002, Alzet, Cupertino, CA, USA) implanted subcutaneously in the dorsal region under isoflurane anesthesia (1–2% isoflurane in oxygen, Baxter, Deerfield, IL, USA) and incisions closed with 2–3 sutures. Pumps were filled with 100 µl of: (a) BQ-123 (0.407 mg/mL dissolved in saline; American Peptide, Sunnyvale, CA, USA), a selective ETA antagonist; (b) BQ-788 (0.509 mg/mL dissolved in propylene glycol; American Peptide, Sunnyvale, CA, USA), a selective ETB antagonist; (c) saline (vehicle for BQ-123) or (d) propylene glycol (vehicle for BQ-788; Sigma-Aldrich, St. Louis, MO, USA). The osmotic minipumps delivered a constant flow-rate of 0.25 μl/h, resulting in a dose of 200 nmol/kg/day of BQ-123 or BQ-788 in each animal (~25 g body weight).
+ Open protocol
+ Expand
9

Neutrophil Response to ET-1 Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Three hours after treatment with TNFα with or without ET receptor antagonists, mice were anesthetized; blood was collected on EDTA by intracardiac puncture and immediately processed for flow cytometry staining for viability and CD11a, CD11b and CD62L surface expression on Ly5G+ neutrophils (see Online Supplementary Methods).
Isolated human neutrophils were fluorescently labeled with fluo-4-acetoxymethyl ester (Fluo-4-AM; Invitrogen). Neutrophils were incubated with BQ123 or BQ788 (both from Sigma®, Saint-Quentin Fallavier, France) at 10 μmol/L for 15 min and analyzed immediately by flow cytometry (FACSCanto II, BD Biosciences, Sparks, MD, USA). After 2 min of signal acquisition, the analysis was interrupted for less than 10 s to add 100 nM of ET-1 (Sigma®) to the tube before the analysis was resumed.
+ Open protocol
+ Expand
10

Intradermal Microdialysis for Endothelin-1 and Norepinephrine

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four intradermal microdialysis fibers were placed and randomly assigned for the local delivery of lactated Ringer’s solution (two sites), 500nmol/L BQ-123 (ETAR-inhibition; Sigma, St. Louis, MO)(35 (link)), or 300nmol/L BQ-788 (ETBR-inhibition; Sigma, St. Louis, MO)(35 (link), 36 (link)). Following baseline measurements, one Ringer’s site and the two inhibited sites received ascending concentrations of ET-1 (10-20-10-8 mol/L; Tocris, Ellisville, MO) while the other Ringer’s site received ascending concentrations of norepinephrine (NE; 10-12-10-2 mol/L; Sigma, St. Louis, MO).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!